Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had prostate cancer come back after previous radiation treatment (such as brachytherapy, external beam radiotherapy, or stereotactic radiotherapy), confirmed by a biopsy
- People whose cancer has been assessed by MRI scan (or ultrasound and CT scan if MRI is not possible) and appears to be confined to one specific area
- People for whom imaging tests (CT, MRI, or PET scan) have shown no signs of cancer that has spread to other parts of the body
- People whose PSA level is rising slowly, with the time it takes to double being longer than six months
- People with a PSA blood test result below 10 ng/ml
- People who have not received any anti-androgen (hormone-blocking) treatment in the past year
- People whose urinary symptom score on a standard questionnaire (called the IPSS) is 20 points or lower
- People whose general health and ability to carry out daily activities meets a standard medical rating of 2 or below on the WHO scale
- People who are willing to sign a consent form agreeing to take part in the study
Who may not be able to join:
- People with a PSA blood test result above 10 ng/ml
- People whose general health rating is above 2 on the WHO scale
- People whose urinary symptom score on the IPSS questionnaire is above 20 points
- People whose PSA level is doubling in less than 6 months
- People who are unable to stop taking blood-thinning medications
- People who currently have an active urinary tract infection
- People who have medical reasons that prevent them from safely receiving general anaesthesia
- People who have active inflammatory bowel disease
- People who currently have another active cancer, or who completed treatment for another cancer less than 3 years ago (except for early-stage skin cancer)
- People whose estimated life expectancy is less than 5 years
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wojciech Burchardt, PhD, MD, Greater Poland Cancer Centre / Brachytherapy Department
Phone: +48505149659
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assessment of the change in the urological toxicity in points with the International Prostate Symptoms Scale; Assessment of the change in the erectile function in points with the International Index of Erectile Function 5 (IIEF-5) (0-25 points); Assessment of the change in the quality of life in points with EORTC C30 and PR25 protocols. (0-100 points)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.